Management of Crigler-Najjar syndrome.

Med Pharm Rep

Department of Internal Medicine, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.

Published: August 2021

Crigler-Najjar syndrome is a rare autosomal recessive inherited non-hemolytic unconjugated hyperbilirubinemia caused by UDP-glucuronosyltransferase deficiency. There are two forms of this disorder. Type 1 disease is associated with severe jaundice and neurologic impairment due to bilirubin encephalopathy that can result in permanent neurologic sequelae. Type 2 disease is associated with a lower serum bilirubin concentration and affected patients survive into adulthood without neurologic impairment. Currently, liver transplantation is the only available therapeutic method for these patients. Developing new curative approaches is a clinical need.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411811PMC
http://dx.doi.org/10.15386/mpr-2234DOI Listing

Publication Analysis

Top Keywords

crigler-najjar syndrome
8
type disease
8
disease associated
8
neurologic impairment
8
management crigler-najjar
4
syndrome crigler-najjar
4
syndrome rare
4
rare autosomal
4
autosomal recessive
4
recessive inherited
4

Similar Publications

Crigler-Najjar syndrome is an ultra-rare monogenic recessive liver disease caused by gene mutations. Complete UGT1A1 deficiency results in severe unconjugated hyperbilirubinemia in newborns that, if not treated, may lead to brain damage and death. Treatment is based on intensive phototherapy, but its efficacy decreases with age, rendering liver transplantation the only curative option.

View Article and Find Full Text PDF

Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review.

Int J Mol Sci

October 2024

Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy.

Article Synopsis
  • Crigler-Najjar Syndrome (CNS) is a rare genetic disorder that leads to severe jaundice due to impaired processing of bilirubin, with two forms: CNS type 1 (more severe) and CNS type 2 (milder).
  • The management of CNS1 is aggressive, often requiring liver transplantation as the only definitive treatment, while CNS2 can be managed with medications like phenobarbital.
  • New therapies, including gene therapy and autologous hepatocyte transplantation, are emerging as potential alternatives to surgery, aiming to enhance treatment effectiveness and improve life quality for CNS patients.
View Article and Find Full Text PDF

Analysis of UGT1A1 genotype-phenotype correlation in Chinese patients with gilbert and crigler-Najjar II syndrome.

Eur J Med Genet

October 2024

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. Electronic address:

Article Synopsis
  • The study examined UGT1A1 gene variants in 310 Chinese patients with Gilbert syndrome (GS) and Crigler-Najjar syndrome (CNS-II) to understand genotype-phenotype correlations.
  • A total of 21 different UGT1A1 variants were identified, including nine that were previously unknown, with a distinct variant pattern compared to Western populations.
  • The research found significant differences in serum total bilirubin and triglyceride levels among various genotypes, indicating how specific UGT1A1 variants affect clinical outcomes in patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!